EczemaPhase 3NCT01257061
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
A Phase 3 study testing Group 1 and Group 2 in people with Eczema, run by EMS at 1 site in Brazil.
Trial summary
Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g + dexamethasone 0, 5 mg/g compared to… Read more about this study
- Who is it for?
- Ages 5 to 50 years
- Conditions the study is for
- Eczema
- What is being tested?
- Group 1 and Group 2
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 310 participants
- Where
- 1 siteBrazil
- Study dates
- 6 Sep 2012to 2 Aug 2013
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 50 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients must be able to understand the study procedures agree to participate and give written consent.
- Patients with acute or sub-acute eczema.
- Presence of symmetric lesions to compare on side to the other.
Who cannot join
- Pregnancy or risk of pregnancy.
- Lactation
- Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).
- Sunlight over exposure in the last 15 days.
- Any pathology or past medical condition that can interfere with this protocol.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.
Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g + dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
Read the detailed description
Study design:
- Double blinded, superiority, prospective parallel-group, intend to treat trial.
Study design:
- Experiment duration: 22 days
- 2 visits (days 1,7,15 and 22)
- Reducing Eczema Area and severity index evaluation
- Adverse events evaluation
- Conditions
- Eczema
- Being tested
- Group 1, Group 2
- Keywords
- Dermatitis, Dermatitis, Atopic
- Medical subject headings
- Eczema, Dermatitis, Dermatitis, Atopic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1Drug
Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
Group 2Drug
Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g Receives: Drug: Group 1 |
| Group 2 | Active comparator | Dexchlorpheniramine maleate 10 mg/g Receives: Drug: Group 2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction / improvement of signs and symptoms
The reduction of signs an symptoms will be evaluated by OSAAD index.
Measured: DAY 22
Secondary outcomes (1)
Adverse Events Evaluation
Adverse events will be collected and followed in order to evaluate safety and tolerability.
Measured: DAY 22
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2010 (estimated)
- Study start6 Sep 2012
- Primary completion30 Apr 2013
- Study completion2 Aug 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EczemaStudies of the same condition, open and under way.
- More trials run by EMSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 310 participants (actual)
Sponsor and investigators
- Lead sponsor
- EMS
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Flavia Addor, MD, Principal investigator, Medcin Instituto da PeleFelipe Pinho, MD, Study director, EMS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01257061
- Sponsor's protocol ID
- DECEMS1010
- Status last verified
- Jun 2020
- First submitted
- 29 Nov 2010
- Last updated
- 7 Jul 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.
- ClinicalTrials.gov ID
- NCT01257061
- Acronym / sponsor ID
- DECEMS1010
- Conditions
- Eczema
- Keywords
- Dermatitis, Dermatitis, Atopic
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 310 participants (actual)
- Lead sponsor
- EMSIndustry (pharma, biotech, devices)
- Study start
- 6 Sep 2012 (actual)
- Primary completion
- 30 Apr 2013 (actual)
- Study completion
- 2 Aug 2013 (actual)
- First posted
- 9 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g + dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
Detailed description
Study design:
- Double blinded, superiority, prospective parallel-group, intend to treat trial.
Study design:
- Experiment duration: 22 days
- 2 visits (days 1,7,15 and 22)
- Reducing Eczema Area and severity index evaluation
- Adverse events evaluation
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Drug: Group 1Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g |
| Group 2 | Active comparator | Drug: Group 2Dexchlorpheniramine maleate 10 mg/g |
Who may qualify
- Ages
- 5 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Patients must be able to understand the study procedures agree to participate and give written consent.
- Patients with acute or sub-acute eczema.
- Presence of symmetric lesions to compare on side to the other.
Key exclusion criteria (5 listed)
- Pregnancy or risk of pregnancy.
- Lactation
- Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).
- Sunlight over exposure in the last 15 days.
- Any pathology or past medical condition that can interfere with this protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion | Drug | Group 1 |
| Group 2Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion | Drug | Group 2 |
Primary outcome
Reduction / improvement of signs and symptoms
Time frame: DAY 22
The reduction of signs an symptoms will be evaluated by OSAAD index.
1 secondary outcome
Adverse Events Evaluation
Time frame: DAY 22
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2020.
Related trials for Eczema
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Flavia Addor, MD principal investigator
Medcin Instituto da Pele
Felipe Pinho, MD study director
EMS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Group 1 and Group 2 in people with Eczema, run by EMS at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction / improvement of signs and symptoms (time frame: DAY 22). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2020.